Literature DB >> 20823836

Potential precipitating factors of esophageal variceal bleeding: a case-control study.

Wei-Chih Liao1, Ming-Chih Hou, Chen-Jung Chang, Fa-Yauh Lee, Han-Chieh Lin, Shou-Dong Lee.   

Abstract

OBJECTIVES: Valsalva maneuver-associated activities such as straining during defecation, vomiting, and cough are believed to cause abrupt increase in variceal pressure. Whether these actions can precipitate rupture of esophageal varices (EV) is unknown. The association of EV bleeding with these activities and other potential risk factors such as ingestion of alcohol and non-steroidal anti-inflammatory drugs was investigated.
METHODS: Between January 2003 and May 2009, 240 patients with liver cirrhosis and acute EV bleeding (group A) and 240 matched patients with Child-Pugh's class and moderate size EV without bleeding (group B) were included. Each patient was questioned regarding constipation, vomiting, cough, and other potential risk factors in the week prior to index bleeding (group A) or endoscopy (group B) using a standard questionnaire.
RESULTS: Group A had more patients with constipation (n=44 vs. n=16, P<0.001) and higher constipation scores (0.79 ± 1.67 vs. 0.25 ± 0.92, P<0.001) than group B. Group A also had more patients with vomiting (n=60 vs. n=33, P=0.002) and higher vomiting scores (3.0 ± 0.86 vs. 1.85 ± 0.87, P<0.001). No difference in cough existed between the two groups (n=77 group A vs. n=73 group B); however, group A had higher cough scores (5.08 ± 2.70 vs. 3.19 ± 2.23, P<0.001). Group A had more patients with excessive alcohol consumption in the week preceding inclusion in the study (n=58 vs. n=5, P<0.001). On multivariate analysis, constipation score and vomiting score and alcohol consumption were independent determinants of first EV bleeding.
CONCLUSIONS: Constipation, vomiting, severe coughing, and excessive consumption of alcohol may precipitate rupture of EV. A prospective cohort study is required to clarify the causal relationship between potential precipitating factors and EV bleeding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823836     DOI: 10.1038/ajg.2010.342

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  A fourfold increase of oesophageal variceal bleeding in cirrhotic patients with a history of oesophageal variceal bleeding.

Authors:  Tsung-Hsing Hung; Chih-Wei Tseng; Chih-Chun Tsai; Chorng-Jang Lay; Chen-Chi Tsai
Journal:  Singapore Med J       Date:  2015-11-25       Impact factor: 1.858

2.  Presence of columnar-lined esophagus is negatively associated with the presence of esophageal varices in Japanese alcoholic men.

Authors:  Akira Yokoyama; Kenro Hirata; Rieko Nakamura; Tai Omori; Takeshi Mizukami; Junko Aida; Katsuya Maruyama; Tetsuji Yokoyama
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

3.  Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway.

Authors:  John Willy Haukeland; Milada Cvancarova Småstuen; Pia Pernille Pålsdatter; Moonisah Ismail; Zbigniew Konopski; Kristin Kaasen Jørgensen; Hans Lannerstedt; Håvard Midgard
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

4.  Is propofol safe when administered to cirrhotic patients during sedative endoscopy?

Authors:  Sang Jun Suh; Hyung Joon Yim; Eileen L Yoon; Beom Jae Lee; Jong Jin Hyun; Sung Woo Jung; Ja Seol Koo; Ji Hoon Kim; Kyung Jin Kim; Rok Son Choung; Yeon Seok Seo; Jong Eun Yeon; Soon Ho Um; Kwan Soo Byun; Sang Woo Lee; Jai Hyun Choi; Ho Sang Ryu
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

5.  Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease.

Authors:  Sophie Restellini; Nicolas Goossens; Sophie Clément; Nicolas Lanthier; Francesco Negro; Laura Rubbia-Brandt; Laurent Spahr
Journal:  World J Hepatol       Date:  2018-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.